These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30312728)

  • 41. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
    Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
    Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway.
    An H; Kim JY; Lee N; Cho Y; Oh E; Seo JH
    Biochem Biophys Res Commun; 2015 Oct; 466(4):696-703. PubMed ID: 26407842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer.
    Lampis A; Hahne JC; Gasparini P; Cascione L; Hedayat S; Vlachogiannis G; Murgia C; Fontana E; Edwards J; Horgan PG; Terracciano L; Sansom OJ; Martins CD; Kramer-Marek G; Croce CM; Braconi C; Fassan M; Valeri N
    Cell Death Differ; 2021 Oct; 28(10):2970-2982. PubMed ID: 34226680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aberrant expression of junctional adhesion molecule-A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155.
    Murakami T; Takasawa A; Takasawa K; Akimoto T; Aoyama T; Magara K; Saito Y; Ota M; Kyuno D; Yamamoto S; Hasegawa T; Saito T; Osanai M
    Cancer Sci; 2021 Feb; 112(2):906-917. PubMed ID: 33185939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
    Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
    PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The junctional adhesion molecule (JAM) family members JAM-2 and JAM-3 associate with the cell polarity protein PAR-3: a possible role for JAMs in endothelial cell polarity.
    Ebnet K; Aurrand-Lions M; Kuhn A; Kiefer F; Butz S; Zander K; Meyer zu Brickwedde MK; Suzuki A; Imhof BA; Vestweber D
    J Cell Sci; 2003 Oct; 116(Pt 19):3879-91. PubMed ID: 12953056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dysregulation of JAM-A plays an important role in human tumor progression.
    Zhao C; Lu F; Chen H; Zhao X; Sun J; Chen H
    Int J Clin Exp Pathol; 2014; 7(10):7242-8. PubMed ID: 25400822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling.
    Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
    Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF; Kane SE; Sonenshein GE
    Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease.
    Vetrano S; Rescigno M; Cera MR; Correale C; Rumio C; Doni A; Fantini M; Sturm A; Borroni E; Repici A; Locati M; Malesci A; Dejana E; Danese S
    Gastroenterology; 2008 Jul; 135(1):173-84. PubMed ID: 18514073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blockage of conformational changes of heat shock protein gp96 on cell membrane by a α-helix peptide inhibits HER2 dimerization and signaling in breast cancer.
    Li X; Wang B; Liu W; Gui M; Peng Z; Meng S
    PLoS One; 2015; 10(4):e0124647. PubMed ID: 25898135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.